{"id":38138,"date":"2025-07-29T16:24:47","date_gmt":"2025-07-29T08:24:47","guid":{"rendered":"https:\/\/flcube.com\/?p=38138"},"modified":"2025-07-29T16:24:47","modified_gmt":"2025-07-29T08:24:47","slug":"yoltechs-yolt-203-gains-orphan-drug-designation-for-primary-hyperoxaluria-type-1-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38138","title":{"rendered":"YolTech&#8217;s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment"},"content":{"rendered":"\n<p>China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation (ODD) to YOLT-203, an investigational in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). This designation underscores the potential of YOLT-203 to address a significant unmet medical need in this rare genetic disorder.<\/p>\n\n\n\n<p><strong>YOLT-203 Mechanism<\/strong><br>YOLT-203 is designed to be a one-time treatment for PH1, a rare genetic disorder that causes kidney stone accumulation and potentially kidney failure. The therapy works by deactivating glycolate oxidase (GO), an enzyme encoded by the HAO1 gene, thereby reducing oxalate overproduction in PH1 patients and suppressing the synthesis of oxalate precursors.<\/p>\n\n\n\n<p><strong>Clinical Trial Progress<\/strong><br>YOLT-203 is currently being evaluated in an ongoing investigator-initiated clinical trial (NCT06511349). Interim data from the trial have demonstrated excellent safety and a strong potential to significantly reduce urinary oxalate levels in patients with PH1. These findings highlight YOLT-203&#8217;s promise as a transformative treatment option for PH1 patients.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38140,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[24,1168],"class_list":["post-38138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-rare-orphan-disease-drugs","tag-yoltech-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>YolTech&#039;s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation (ODD) to YOLT-203, an investigational in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). This designation underscores the potential of YOLT-203 to address a significant unmet medical need in this rare genetic disorder.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38138\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YolTech&#039;s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation (ODD) to YOLT-203, an investigational in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). This designation underscores the potential of YOLT-203 to address a significant unmet medical need in this rare genetic disorder.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38138\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-29T08:24:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2917.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"YolTech&#8217;s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment\",\"datePublished\":\"2025-07-29T08:24:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138\"},\"wordCount\":180,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2917.webp\",\"keywords\":[\"Rare \\\/ orphan disease drugs\",\"YolTech Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38138#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38138\",\"name\":\"YolTech's YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2917.webp\",\"datePublished\":\"2025-07-29T08:24:47+00:00\",\"description\":\"China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation (ODD) to YOLT-203, an investigational in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). This designation underscores the potential of YOLT-203 to address a significant unmet medical need in this rare genetic disorder.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38138\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2917.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2917.webp\",\"width\":1080,\"height\":608,\"caption\":\"YolTech's YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38138#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YolTech&#8217;s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"YolTech's YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation (ODD) to YOLT-203, an investigational in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). This designation underscores the potential of YOLT-203 to address a significant unmet medical need in this rare genetic disorder.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38138","og_locale":"en_US","og_type":"article","og_title":"YolTech's YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment","og_description":"China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation (ODD) to YOLT-203, an investigational in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). This designation underscores the potential of YOLT-203 to address a significant unmet medical need in this rare genetic disorder.","og_url":"https:\/\/flcube.com\/?p=38138","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-29T08:24:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2917.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38138#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38138"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"YolTech&#8217;s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment","datePublished":"2025-07-29T08:24:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38138"},"wordCount":180,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2917.webp","keywords":["Rare \/ orphan disease drugs","YolTech Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38138#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38138","url":"https:\/\/flcube.com\/?p=38138","name":"YolTech's YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38138#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2917.webp","datePublished":"2025-07-29T08:24:47+00:00","description":"China-based YolTech Therapeutics announced that the European Medicines Agency\u2019s (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation (ODD) to YOLT-203, an investigational in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). This designation underscores the potential of YOLT-203 to address a significant unmet medical need in this rare genetic disorder.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38138#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38138"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38138#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2917.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2917.webp","width":1080,"height":608,"caption":"YolTech's YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38138#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"YolTech&#8217;s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2917.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38138"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38138\/revisions"}],"predecessor-version":[{"id":38141,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38138\/revisions\/38141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38140"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}